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Assessing Pharmacodynamic Interactions in Mice Using
the Multistate Tuberculosis Pharmacometric and General
Pharmacodynamic Interaction Models
Chunli Chen1,2,3, Sebastian G. Wicha1, Gerjo J. de Knegt4, Fatima Ortega5, Laura Alameda5, Veronica Sousa5,
Jurriaan E. M. de Steenwinkel4 and Ulrika S. H. Simonsson1*
The aim of this study was to investigate pharmacodynamic (PD) interactions in mice infected with Mycobacterium
tuberculosis using population pharmacokinetics (PKs), the Multistate Tuberculosis Pharmacometric (MTP) model, and the
General Pharmacodynamic Interaction (GPDI) model. Rifampicin, isoniazid, ethambutol, or pyrazinamide were administered in
monotherapy for 4 weeks. Rifampicin and isoniazid showed effects in monotherapy, whereas the animals became moribund
after 7 days with ethambutol or pyrazinamide alone. No PD interactions were observed against fast-multiplying bacteria.
Interactions between rifampicin and isoniazid on killing slow and non-multiplying bacteria were identified, which led to an
increase of 0.86 log10 colony-forming unit (CFU)/lungs at 28 days after treatment compared to expected additivity (i.e.,
antagonism). An interaction between rifampicin and ethambutol on killing non-multiplying bacteria was quantified, which led
to a decrease of 2.84 log10 CFU/lungs at 28 days after treatment (i.e., synergism). These results show the value of
pharmacometrics to quantitatively assess PD interactions in preclinical tuberculosis drug development.
CPT Pharmacometrics Syst. Pharmacol. (2017) 00, 00; doi:10.1002/psp4.12226; published online on 0 Month 2017.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 There is limited knowledge on the PD interactions
between standard TB drugs due to a lack of a quantita-
tive framework for their assessment.
WHAT QUESTION DID THIS STUDY ADDRESS?
 It addressed how to quantitatively assess drug-drug
PD interactions between two drugs in more than two-
drug combination therapies using sparse mice data.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 The application of the MTP model together with the
GPDI model in TB-infected BALB/c mice could describe
untreated mice or mice treated with rifampicin, isonia-
zid, ethambutol, and pyrazinamide mono therapy, as
well as an assessment of antagonistic interactions (less
than expected additivity) between rifampicin and isonia-
zid and synergistic interactions (more than expected
additivity) between rifampicin and ethambutol in combi-
nation therapies using a model-based approach.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 Even with sparse animal data, PK-PD relationships
with PD interactions using the MTP-GPDI model could
be assessed, which provides information for phase II
and phase III trials for translational development of
novel combination therapies in TB drug development.
In 2015, approximately 1.8 million people died from Myco-
bacterium tuberculosis (M. tuberculosis) and 10.4 million
new cases were reported worldwide.1 No regimen has yet
proven to be superior to the standard regimen for drug-
susceptible tuberculosis (TB), which consists of a 2-month
initial phase of rifampicin, isoniazid, pyrazinamide, and eth-
ambutol followed by a 4-month continuation phase of rifam-
picin and isoniazid. Due to the development of drug
resistance, long treatment periods cause a high risk of low
patient adherence as well as disease relapse in patients.
New drugs or combinations are highly needed to overcome
these obstacles. Potential pharmacodynamic (PD) drug-
drug interactions (i.e., a lower (antagonism) or higher effect
(synergism) compared to expected additivity, such as add-
ing each drug effect in monotherapy), present a difficulty
arising from combination therapies. The PD interactions are
difficult to assess in a clinical setting, especially in the field
of antitubercular drug development in which regimens con-
tain two or more drugs. Hence, preclinical systems have to
fill this knowledge gap, but evaluation of PD interactions
has been methodologically challenging.2
The General Pharmacodynamic Interaction (GPDI) model
provides a model-based assessment of PD interactions
given as fractional changes of PD parameters of monother-
apy effects, which was originally developed and presented
by Wicha et al.3 In contrast to other approaches, the GPDI
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model is applicable for more than two potentially interacting
drugs, which is of key importance in TB drug development.
A key feature of the GPDI approach is that interactions are
quantified on the level of PD parameters and not on the pure
effect level. Thereby, the GPDI approach is capable, in addi-
tion to determine pure synergistic or antagonistic interac-
tions, to detect asymmetric interactions (i.e., in which both
synergism and antagonism occur between two drugs over a
concentration range or study time period). In addition, an
advantage of the GPDI model compared with other traditional
approaches is that it can estimate the interaction between an
inactive perpetrator and an active victim drug. Moreover, the
GPDI approach can be parameterized in different complexity
and, hence, be used for both sparse and rich data.
The Multistate Tuberculosis Pharmacometric (MTP) model,
predicting the change in bacterial numbers of fast, slow, and
non-multiplying bacteria, with and without drug effects, is a
semimechanistic pharmacokinetic (PK) and PD model for
studying antitubercular drug effects and was developed
using in vitro data.4 The MTP model has successfully been
used to describe rifampicin efficacy in an acute C57BL/6
mouse model using differences in colony-forming units
(CFUs) over time,5 and has also been applied to clinical
data in order to estimate the drug efficacy of human early
bacterial activity and to perform clinical trial simulations.6
The aim of this work was to use the MTP model
approach to describe the drug effects of rifampicin, isonia-
zid, ethambutol, and pyrazinamide in the monotherapy in a
BALB/c mouse model using biomarker CFU data. In addi-
tion, we aimed to link the MTP model to the GPDI model in
order to assess PD interactions in combination therapies.
MATERIALS AND METHODS
Chemicals
Ethambutol and pyrazinamide were obtained from Sigma-
Aldrich (Zwijndrecht, The Netherlands) and isoniazid was
obtained from the hospital pharmacy (Rotterdam, The Neth-
erlands). Compounds were dissolved in distilled water.
Rifampicin was obtained from Sanofi-Aventis (Gouda, The
Netherlands), dissolved in the supplemented dissolvent,
and further diluted in water.
Animals
Specified pathogen-free female BALB/c mice (13–15 weeks
old, weighing 20–25 g) were obtained from Charles River
(Les Oncins, France). Experimental protocols adhered to
the rules specified in the Dutch Animal Experimentation Act
and were in concordance with the European Union (EU)
animal directive 2010/63/EU. The Institutional Animal Care
and Use Committee of the Erasmus Medical Center
approved the present protocols (117-12-08 and 117-12-13).
Mice were infected, as previously described.7 In brief,
mice under anesthesia were infected through intratracheal
instillation of a suspension (40 mL) containing 9.5 3 104
CFU of the Beijing VN 2002-1585 genotype strain, followed
by proper inhalation to ensure the formation of a bilateral
TB infection.8
Anti-TB treatment
In this study, the doses were chosen based on the human-
equivalent dose of each antitubercular compound. There
were three dose levels chosen for each drug, 0.5 3 human-
equivalent dose, 1 3 human-equivalent dose, and 2 3
human-equivalent dose. All treatments started 14 days after
infection. Monotherapy of rifampicin at dose levels at 5, 10,
and 20 mg/kg (R5, R10, and R20, respectively), isoniazid at
12.5, 25, and 50 mg/kg (H12.5, H25, and H50, respectively),
ethambutol at 50, 100, and 200 mg/kg (E50, E100, and E200,
respectively) or pyrazinamide at 75, 150, and 300 mg/kg
(Z75, Z150, and Z300, respectively) were orally administered
daily for 5 days per week via oral gavage, lasting for 4
weeks.8 The CFU counts were assessed in monotherapy
after 1, 2, and 4 weeks of treatment with isoniazid or rifampi-
cin, using 9 mice per time point, including 3 mice per dose
level. The CFU counts were only obtained from 6 mice after 1
week of treatment with pyrazinamide and ethambutol,
because the mice did not survive beyond 1 week with treat-
ments of pyrazinamide or ethambutol. Fixed doses were
used in combination therapies, including R10, H25, E100, and
Z150. Combination therapies (R10H25, R10H25Z150, and
R10H25Z150E100) lasted up to 24 weeks. The CFU counts
were assessed in drug combinations after 1, 2, 4, 8, 12, and
24 weeks of treatment with 3 mice at each occasion. Bacte-
rial natural growth (i.e., no treatment), was collected at 1, 3,
7, 14, and 21 days after infection.
Population pharmacokinetic study and modeling
The PK information was obtained from TB-infected mice
and was used for assessing PD in monotherapy. One blood
sample per mouse was drawn from infected mice (n5 49)
after 4 weeks of treatment with rifampicin (R5, R10, or R20),
isoniazid (H12.5, H25, or H50), and after 1 week of treatment
with ethambutol (E50, E100, or E200) or pyrazinamide (Z75,
Z150, or Z300) at 1, 4, and 8 hours after dose with 3 mice
per time point. Mice receiving Z75 in monotherapy only con-
tributed CFU data and not PK data. The PK sampling was
different for mice treated with pyrazinamide or ethambutol,
as the treatment results in no survival beyond 1 week with
treatments. Drug plasma samples from infected mice were
frozen at 2808C and processed by protein precipitation
with organic solvents plus filtration. Samples were then
analyzed by ultraperformance liquid chromatography tan-
dem mass-spectrometry for quantification of each drug at
GlaxoSmithKline. To support the population pharmacoki-
netic (PopPK) model development for rifampicin, drug con-
centrations from the sparsely sampled TB-infected mice
were combined with a second PK study in healthy mice
(n5 18).8 Healthy mice were administered R10 or R160 for 5
days a week for 3 weeks and the PK was obtained at 0.08,
0.25, 0.5, 0.75, 1.5, 3, and 6 hours after the last dose (one
sample per mouse). Rifampicin, quantified in plasma sam-
ples from healthy mice, was measured by protein precipita-
tion, followed by high-performance liquid chromatography
with ultraviolet detection.9
All plasma concentrations of each drug were pooled and
modeled simultaneously. One and two compartment distri-
bution models with first-order absorption and elimination
were evaluated. Because of lack of data in the absorption
phase, the absorption rate constant (ka) of isoniazid, eth-
ambutol, and pyrazinamide was fixed to values from a pre-
vious study.10 Differences in PK between healthy and
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infected mice were evaluated. Similarly, concentration-
dependencies or time-dependencies in all PK parameters
were evaluated. Because only one sample was taken from
each mouse, interindividual variability in PK was not quanti-
fied. A PopPK parameter approach was used as input and
linked to the MTP model.11
Evaluation of drug effects in monotherapy
The MTP model, consisting of fast-multiplying (F), slow-
multiplying (S), and non-multiplying (N) bacteria was used
for the PD modeling of CFU data from each drug. The dif-
ferential equation system for F (Eq. 1), S (Eq. 2), and N
(Eq. 3) was as follows:
dF
dt
5kG  F1kSF  S2kFS  F2kFN  F (1)
dS
dt
5kFS  F1kNS  N2kSF  S2kSN  S (2)
dN
dt
5kSN  S2kNS  N1kFN  F (3)
where kG is the growth rate of F, kFS, kSF, kFN, kSN, and kNS
are transfer rates between each bacterial state and F, S,
and N represent fast, slow, and non-multiplying bacteria,
respecitvely.
Initially, only CFU data without treatment were evaluated.
The first-order transfer rates from S to F (kSF), from S to N
(kSN), from N to S (kNS), and from F to N (kFN) were fixed
according to the original in vitro study.4 The transfer of F to
S (kFS) increased linearly with time in the MTP model
applied to in vitro data and was re-evaluated using maxi-
mum effect (Emax) and linear functions with respect to time
in this study. A re-estimation of kFS as well as the other
transfer rates, one at a time, was compared to fixing the
parameter to the in vitro estimates.4 Gompertz, Emax, and
linear growth functions were evaluated to describe the
growth rate (kG) of F in this mouse model.
All parameters associated with natural growth (kG, kFS,
kSF, kFN, kSN, and kNS) were fixed during the estimation of
drug effects. The effect of each drug was first evaluated
using only monotherapy data. The effects of monotherapy
were evaluated as inhibition of the growth of F, and/or stim-
ulation of the death on each of the three bacterial states
using an on/off effect, a linear function (Eq. 4), an ordinary
Emax function (Eq. 5), or a sigmoidal Emax function (Eq. 6).
Edrug5k  Cdrug (4)
Edrug5
Emax  Cdrug
EC501Cdrug
(5)
Edrug5
Emax  Cdrugc
EC50
c1Cdrug
c (6)
where Cdrug represents drug concentration; k is the kill rate
for each drug in monotherapy; Emax is the maximal achiev-
able drug effect for each drug; EC50 is the drug concentra-
tion at 50% of Emax for each drug; c is a sigmoidicity
parameter, and Edrug expresses the drug effect in mono-
therapy. In the following step, all identified drug effects from
monotherapy were combined and evaluated for statistical
significance (P<0.05). A final backward evaluation step
(P<0.01) was also done where the effect functions were
reduced to their simpler forms to identify the best model for
each drug in monotherapy.
Evaluation of pharmacodynamic interactions
During the evaluation of PD interactions, data from combi-
nation regimens were pooled with data from natural growth
and data from monotherapy. The MTP model parameters
(kG, kFS, kSF, kFN, kSN, and kNS) and parameters of the
monotherapy final exposure-response relationships were
fixed during the PD interaction assessment. If no drug
effect was identified using only monotherapy, a re-
evaluation using the combination dataset was done with a
similar modeling strategy as for monotherapy data. This
step was required due to the different treatment lengths.
The PD interactions were assessed at each effect site,
including inhibition of the growth of F, and/or stimulation of
the death of F, S, or N.
The Bliss Independence (BI)12 (i.e., EAB5EA1EB-
EA3EB) was used as an additivity criterion for the GPDI
model,3 as the Loewe Additivity13 cannot handle differences
in Emax. As BI was derived from probability theory, all effects
were scaled between 0 and 1 relative to the highest Emax for
BI calculation and then rescaled by the highest Emax, as
described by Wicha et al.14 For slope models, the BI was
simplified to EAB5EA1EB due to the minor contribution of
EAEB at concentrations well below the EC50 when linear
models are identified. Hence, the drug effects of two drugs A
and B can be expressed as in Eq. 7 and Eq. 8. In three and
four-drug combinations, interaction parameters identified in
previous combinations were fixed. In the final MTP-GPDI
model, all parameters were estimated simultaneously.
EA5
EmaxA3C
HA
A
EC50A 3 11
INTAB3CB
HINT ;B
EC50INT ;AB
HINT ;B1CB
HINT ;B
  HA
1CA
HA
(7)
EB5
EmaxB3C
HB
B
EC50B 3 11
INTBA3CA
HINT ;A
EC50INT ;BA
HINT ;A1CA
HINT ;A
  HB
1CB
HB
(8)
where INTAB and INTBA characterize the maximum frac-
tional change of the respective PD parameters. An esti-
mated value of zero of INTAB or INTBA suggested no
interaction. A positive value suggested decreased drug
potency, whereas a value between 21 and 0 suggested
increased drug potency caused by interaction between the
two drugs. EC50INT,AB and EC50INT,BA represent the inter-
action potencies. HINT,A and HINT,B represent the interaction
sigmoidicities.
Due to the fact that few exposure levels were included in
the combination therapy data in this study, a joint INTAB
was estimated (INTAB5 INTBA) and EC50INT was set to a
very low value of 1 3 1028, which reduced the Emax func-
tion to an on/off effect, which was used in evaluating the
PD interaction. Equation 9 shows an example of a reduced
GPDI model for the evaluation of a joint effect of drugs A
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and B when the exposure-response relationship was
defined using a slope model, and on/off interaction with a
joint interaction term INTAB:
EAB5CA  kA11INTAB 1CB 
kB
11INTAB
(9)
where kA and kB are linear effects of drug A and drug B
identified in monotherapy.
Model evaluation and selection
All modeling was done using the software NONMEM ver-
sion 7.3 (Icon Development Solutions (http://www.iconplc.
com/technology/products/nonmem), Ellicott City, MD) using
the first-order conditional estimation method.15 Model evalu-
ation and selection were based on the objective function
value (OFV) with a decrease of 3.84 considered statistically
significant (P<0.05, v2 distribution) for nested models and
one degree of freedom. In addition, goodness-of-fit plots,
parameter precision, predictive performance assessed
using visual predictive check (VPC),16 prediction-corrected
visual predictive checks (pcVPC),17 and scientific plausibil-
ity were used for model selection. In both pcVPC and VPC,
1,000 replicates were simulated based on the model and
fifth, median, and 95th percentiles were used in conjunction
with the corresponding data to assess model performance
using Perl-speaks-NONMEM (PsN) version 4.2.0 (http://
psn.sourceforge.net), Department of Pharmaceutical Biosci-
ences, Uppsala University, Sweden).16 The R package
Xpose version 4.4.1 (http://xpose.sourceforge.net), Depart-
ment of Pharmaceutical Biosciences, Uppsala University,
Sweden) was used for visualization of results and data
management.16 The run record was produced with Pirana
software version 2.7 (Pirana Software and Consulting
(http://www.pirana-software.com), San Francisco, CA).18
The M3 method in NONMEM was used to handle data
below the lower limit of quantification (LLOQ),19 which was
10 CFU/lungs for PD data (5.7% of the dataset) and 10 ng/
mL, 100 ng/mL, 10 ng/mL, and 60 ng/mL of rifampicin
(8.9%), isoniazid (27.8%), ethambutol (0%), and pyrazina-
mide PK data (0%), respectively. Proportional, combined
proportional, and additive error models for PK data and an
additive error model on log scale for PD data were evalu-
ated to describe residual unexplained variability.
RESULTS
Population pharmacokinetic models
The final PopPK models of rifampicin, isoniazid, and pyrazi-
namide were one-compartment models, whereas a two-
compartment model described the ethambutol data well. All
data were well-described using the final PopPK models
(Figure 1) and all PK parameters are shown in Table 1.
The pcVPCs of the final PopPK models are available as
Supplementary Material S1.
The final PopPK model for rifampicin included a separate
apparent clearance (CL/F) in TB-infected mice receiving 4
weeks of rifampicin treatment, which was 3 times higher
than CL/F in healthy mice treated for 3 weeks. In addition,
the CL/F at R160 was 2.5 times lower than for mice that
received lower doses of rifampicin. Apparent volume of dis-
tribution of the central compartment (V/F) after R160
was 1,700 mLkg21, which was larger than V/F at other dose
levels (706 mLkg21). Isoniazid CL/F decreased from
612 mLh21kg21 at lowest dose of 12.5 mg/kg to
440 mLh21kg21. Isoniazid V/F was estimated to
811 mLkg21. Apparent clearance (CL/F) of ethambutol was
estimated to 3,400 mLh21kg21. Ethambutol V/F and appar-
ent volume of distribution of the peripheral compartment
(V2/F) were estimated to 1,500 and 4,690 mLkg21, respec-
tively. Pyrazinamide PK was linear with respect to dose with
CL/F estimated to 273 mLh21kg21 and V/F to 525
mLkg21.
Multistate tuberculosis pharmacometric model
The final model structure of the MTP model describing
changes in CFU over time after treatment with rifampicin,
isoniazid, pyrazinamide, or ethambutol is shown in Figure 1.
The data supported estimation of initial bacterial numbers of
fast-multiplying (F0) and slow-multiplying (S0) bacteria, but
no inoculum of non-multiplying bacteria, which was, there-
fore, set to zero in the final model. Re-estimating the transfer
rate from F to S (kFS) as a linear function with time produced
a decrease in OFV of 22 points compared to fixing the
parameter to the in vitro estimate.4 Re-estimation of the other
transfer rates between the states did not provide a reduction
in OFV and was, therefore, fixed to in vitro estimates.4 An
exponential growth function was used to describe the natural
growth rate of F (kG).
Exposure-response relationships for mono drug
therapy
The final MTP model included rifampicin mono drug effects
on inhibition of the growth of F, and stimulation of the death
of F, S, and N, as well as isoniazid mono drug exposure-
response relationships as linear death rates of both F and
S. Isoniazid effect on stimulation of the death of N was
identified in R10H25Z150 using a linear function, which was
not identifiable in isoniazid monotherapy and R10H25 combi-
nation. All equations of mono drug effects are shown in
Figure 1.
Due to a lack of longitudinal CFU data on ethambutol
and pyrazinamide during monotherapy, the mono drug
effects of these drugs could not be quantified.
General pharmacodynamic interaction model
The GPDI model was linked to the MTP model for the eval-
uation of PD interactions using combination therapies.
Rifampicin and isoniazid decreased their respective poten-
cies on jointly killing S (INTSRH ) and N (INT
N
RH ). INT
S
RH and I
NTNRH were estimated to 4.49 and 0.32, respectively, which
can be interpreted as a 4.49-fold or 0.32-fold decrease in
the efficacy slope of rifampicin and isoniazid, respectively
(Supplementary Material S2). This potency shift leads to
0.86 log10 CFU/lungs higher CFU at 28 days after treat-
ment compared to the expected additivity of the two drugs
based on monotherapy alone (i.e., PD antagonism was
observed on the biomarker level (Figure 2)). Figure 3 illus-
trates simulations from the final MTP-GPDI model and
revealed that antagonistic interactions between rifampicin
and isoniazid were more relevant in the lower dose range
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of rifampicin and higher dose range of isoniazid at 28 days
after treatment.
Rifampicin and ethambutol increased their potencies
(INTNRE5 20.15), as estimated by the GPDI model (Sup-
plementary Material S2). The data did not support any PD
interaction between ethambutol and pyrazinamide. These
PD interactions led to 2.84 log10 CFU/lungs lower CFU
compared to expected additivity between four drugs. PD
parameters are shown in Table 2. An additive residual error
on log scale was used in the final MTP-GPDI model to
describe the residual variability using log transformation of
both sides.
The differential equation system for F (Eq. 10), S
(Eq. 11), and N (Eq. 12) for the final MTP-GPDI model was
as follows:
dF
dt
5FG  F1kSF  S2kFS  F2kFN  F2FD  F (10)
dS
dt
5kFS  F1kNS  N2kSF  S2kSN  S2SD  S (11)
dN
dt
5kSN  S2kNS  N1kFN  F2ND  N (12)
where FG and FD are the inhibition of the growth and stim-
ulation of the death of F, and SD and ND are the stimula-
tion of the death of S and N. Detailed equations of FG, FD,
SD, and ND are shown in Figure 1. The VPCs for no treat-
ment, monotherapies, and combination therapies based on
the final models are shown in Figure 4. The final model
code is available in the Supplementary Material S3.
Figure 1 Schematic illustration of the final population pharmacokinetic (PK) models and the final Multistate Tuberculosis Pharmacomet-
ric model consisting of fast (F), slow (S), and non-multiplying (N) bacterial states linked to the General Pharmacodynamic Interaction
model. The bacterial system was described with a growth rate of F (kGR ), a time-dependent linear rate parameter describing transfer
rate from fast to slow-multiplying bacteria (kFS), first-order transfer rate from slow to fast-multiplying state (kSF), first-order transfer rate
from fast to non-multiplying state (kFN), first-order transfer rate from slow to non-multiplying state (kSN), and first-order transfer rate
from non to slow-multiplying state (kNS). The final PK models of rifampicin (R; in orange), isoniazid (H; in green), ethambutol (E; in pur-
ple) and pyrazinamide (Z; in blue) are shown where the absorption rate constant (ka), clearance (CL), volume of distribution of the cen-
tral and peripheral compartment (V and V2) and intercompartmental clearance (Q) are specified for different drugs with subscription.
The monotherapy drug effects are shown as dashed lines for rifampicin (in orange), isoniazid (in green), ethambutol (in purple), and
pyrazinamide (in blue) affecting the inhibition of the growth of fast-multiplying bacteria (FG) and stimulation of the death of fast-
multiplying bacteria (FD), slow-multiplying bacteria (SD), or non-multiplying bacteria (ND). The kFR is the linear rifampicin-induced inhibi-
tion of fast-multiplying bacteria growth rate in monotherapy. The OOFR is the rifampicin-induced on/off stimulation of fast-multiplying bac-
teria death rate in monotherapy. The kSR and k
N
R are rifampicin-induced second-order slow and non-multiplying bacteria death rates,
respectively, in monotherapy. The kFH , k
S
H , and k
N
H are isoniazid-induced second-order fast, slow, and non-multiplying bacteria death
rates, respectively, in monotherapy. The pharmacodynamic (PD) interactions of rifampicin (R; in orange), isoniazid (H; in green), etham-
butol (E; in purple) and pyrazinamide (Z; in blue) are shown as1 (synergism) or – (antagonism) on the respective dashed drug effect
line. INTSRH and INT
N
RH are the PD interactions on stimulation of the death of slow and non-multiplying bacteria, respectively, observed
between rifampicin and isoniazid in the combination. The INTNRE is the PD interaction on stimulation of the death of non-multiplying bac-
teria, observed between rifampicin and ethambutol in the combination.
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DISCUSSION
In this study, we describe the application of the MTP model
together with the GPDI model using a BALB/c mouse
model in order to describe untreated mice or mice treated
with rifampicin, isoniazid, ethambutol, and pyrazinamide.
The major focus of the work was the assessment of PD
interactions using a model-based approach, which could be
applied to both mono and combination therapies of antitu-
bercular drugs and the biomarker CFU data.
To go beyond simple dose-response characterization, we
included PK information to characterize the (joint)
exposure-response relationship of the antitubercular drugs
studied. To our knowledge, for the first time, our modeling
approach quantified that rifampicin CL/F in TB-infected
mice treated for 4 weeks is three times higher than in
healthy mice treated for 3 weeks. This difference is poten-
tially due primarily to different disease status, but auto-
induction of rifampicin may also contribute to some degree.
The mechanism of action on dose-dependent V/F of rifam-
picin and isoniazid is unknown.
Exposure-response relationships were characterized in
monotherapies by the MTP model. We fixed the transfer
rate between each bacterial state according to an earlier in
vitro study,4 except kFS, which was re-estimated as a linear
function of time. This provided a significant drop in OFV
whereas re-estimation of the other rate constants was not
significant. The CFU data in this study did not contain
enough information about transfer from the other bacterial
states, which was evident in the in vitro data. It has been
demonstrated that the decline in CFU after 60 days of in
vitro incubation is not due to bacterial death. Instead, it is
due to the fact that the bacilli entered into persistent stage
in vitro and in vivo, which can only be woken up by
resuscitation-promoting factors.20 Natural growth rate (kG)
of F was described by an exponential function, due to lack
of plateau information on the bacterial burden. A similar
approach to using (fixing) in vitro information about transfer
between bacterial states was used in a previous study in
the acute C57BL/6 mouse model,5 and in the other study
as well.21 To treat drug-susceptible TB, ethambutol is the
last drug added in the combination of rifampicin, isoniazid,
and pyrazinamide. The major role of ethambutol is to pre-
vent drug resistance in the combination therapy.22 Pyrazi-
namide is effective to the bacterial subpopulation in acid pH
conditions in the lesions.23 However, there is no lesion in
BALB/c mouse model.24 Therefore, no effects of ethambu-
tol and pyrazinamide were observed in monotherapy in this
study.
Pharmacological synergism and antagonism are usually
defined as greater or less than additive effect (additivity) of
combined drugs. Loewe Additivity and BI are two major
competing definitions of additivity. Empirical parametric
interaction approaches, for instance, by using a power func-
tion25 or the Greco model,26 have been used to quantify
how PD interactions lead to differences from additivity.
However, results from these models are more difficult to
interpret, as their interaction parameters have no quantita-
tive meaning and only assess monodimensional symmetric
interaction with single interaction parameter, limited to two
drugs in combination and a single underlying additivity
criterion.
This study quantified, we believe for the first time, the
observed in vivo PD interactions in combination therapies by
using the GPDI model.3 Both BI and Loewe Additivity are
compatible with the GPDI model, which makes the GPDI
model approach more flexible than previously described
approaches. As our studies emphasize, the GPDI model
based on BI is not limited to the two drugs in combination
therapies. A property of the GPDI approach is that asym-
metric interactions can be quantified (i.e., a different effect
of drug A on drug B and vice versa), as shown in Supple-
mentary Material S4. In our study, asymmetric interactions
were not characterized, due to the single-dose level of each
drug in the combination therapy, which led to the assumption
of an on/off effect only estimating INTAB, instead of an Emax
Table 1 Final population pharmacokinetic parameter estimates for rifampicin, isoniazid, ethambutol, and pyrazinamide in mice
Parameters
Rifampicin Isoniazid Ethambutol Pyrazinamide
Typical value RSE, % Typical value RSE, % Typical value RSE, % Typical value RSE, %
ka (h
21) 6.23 21.0 12.6 FIXa - 0.87 FIXa - 2.84 FIXa -
CL/F (mLh21kg21) 234 22.4 612b 5.4 3,400 11.0 273.71 15.9
V/F (mLkg21) 706 32.4 811 8.0 1,500 22.3 525.1 22.1
Q/F (mLh21kg21) - - - - 2,530 42.7 - -
V2/F (mLkg21) - - - - 4,690 27.3 - -
Vhighest dose/F (mLkg21) 1,700 11.6 - - - - - -
CLhighest dose/F (mLh21kg21) 94.6 6.3 - - - - - -
Slope - - 7.50E-03 16.8 - - - -
CL/F (mLh21kg21) 54.9 35.3 - - - - - -
Proportional residual error 0.0419 13.0 0.0174 23.1 0.135 12.0 0.264 13.2
Additive residual error 7.77 35.0 0.232 25.0 0.0239 38.1
CL/F, apparent clearance; CLhighest dose/F, apparent clearance at the highest dose level of 160 mg/kg of rifampicin; CL/F, apparent clearance of rifampicin in
healthy mice; ka, absorption rate constant; V/F, apparent volume of distribution in the central compartment; Vhighest dose/F, apparent volume of distribution at the
highest dose of 160 mg/kg of rifampicin; V2/F, apparent volume of distribution in the peripheral compartment; Q/F, apparent intercompartmental clearance;
RSE, relative standard error reported on the approximate SD scale.
aka fixed according to Chen et al.
10; bCL/Fisoniazid for the lowest dose; CL/Fisoniazid, CL/Flowest dose(1 – Slope (Dose – Doselowest dose)).
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function, which represents a limitation of our study originat-
ing from the sparse experimental data. Scalability of the
GPDI approach to different levels of complexity (i.e., using
the full four-parameter model or a reduced single parameter
model) is a key advantage of this approach over the conven-
tional approaches. Moreover, interaction parameters are
interpretable in the GPDI approach as fractional changes of
the PD parameter (i.e., change of the slope in the present
Figure 2 Predicted change from baseline of log10 colony-forming unit (CFU)/lungs after mono and combination therapies based on the
final Multistate Tuberculosis Pharmacometric-General Pharmacodynamic Interaction model (solid lines) compared to model-predicted
expected additivity (dotted lines) after 10 mg/kg rifampicin monotherapy (R10), 25 mg/kg isoniazid monotherapy (H25), combination
therapy of 10 mg/kg rifampicin and 25 mg/kg isoniazid (R10H25), combination therapy of 10 mg/kg rifampicin, 25 mg/kg isoniazid, and
150 mg/kg pyrazinamide (R10H25Z150), combination therapy of 10 mg/kg rifampicin, 25 mg/kg isoniazid, 150 mg/kg pyrazinamide, and
100 mg/kg ethambutol (R10H25 Z150E100). Observed data are given as symbols. The data did not support any drug effect from pyrazi-
namide or ethambutol in monotherapy. The fluctuations in response are due to drug treatments in 5 of 7 days per week.
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Figure 3 Predicted log10 colony-forming unit (CFU)/lungs in numbers and log10 CFU/lungs deviation from expected additivity (in shaded
areas) for rifampicin and isoniazid in different combinations at 28 days after treatment. White areas in the figure show expected additiv-
ity, whereas blue shaded areas show higher log10 CFU/lungs (antagonism) than expected additivity, and orange shaded areas show
lower log10 CFU/lungs (synergism) than expected additivity.
Table 2 Pharmacodynamic parameter estimates of the final Multistate Tuberculosis Pharmacometric-General Pharmacodynamic Interaction model
Parameter Description Typical value RSE, %
The MTP model
F0 (lungs
21) Initial fast-multiplying bacterial number 20,100 59.2
S0 (lungs
21) Initial slow-multiplying bacterial number 119,000 31.0
kG (h
21) Growth rate of the fast-multiplying bacteria 0.034 10.0
kFSlin (h
22) Time-dependent transfer rate from fast-multiplying to slow-multiplying bacterial state 6.651025 20.3
kSF (h
21) First-order transfer rate from slow to fast-multiplying bacterial state 6.031024 FIXa
kFN (h
21) First-order transfer rate from fast to non-multiplying bacterial state 3.741028 FIXa
kSN (h
21) First-order transfer rate from slow to non-multiplying bacterial state 7.731023 FIXa
kNS (h
21) First-order transfer rate from non to slow-multiplying bacterial state 5.111025 FIXa
kGR Linear rifampicin-induced inhibition of fast-multiplying bacteria growth rate 0.0022 29.2
OOFR (h
21) Rifampicin-induced on/off stimulation of fast-multiplying bacteria death rate 0.019 4.2
kSR (mLh21mg21) Rifampicin-induced second-order slow-multiplying bacteria death rate 0.0137 15.8
kNR (mLh21mg21) Rifampicin-induced second-order non-multiplying bacteria death rate 0.0033 8.0
kFH (mLh21mg21) Isoniazid-induced second-order fast-multiplying bacteria death rate 0.055 15.6
kSH (mLh21mg21) Isoniazid-induced second-order slow-multiplying bacteria death rate 0.00047 53.6
kNH (mLh21mg21) Isoniazid-induced second-order non-multiplying bacteria death rate 0.0012 5.0
The GPDI model
INTSRH Interaction between rifampicin and isoniazid on stimulation of the death of slow-multiplying bacteria 4.49 28.1
INTNRH Interaction between rifampicin and isoniazid on stimulation of the death of non-multiplying bacteria 0.32 38.0
INTNRE Interaction between rifampicin and ethambutol on stimulation of the death slow-multiplying bacteria 20.15 57.7
r2 Additive residual variability on log scale (variance) 1.23 16.7
E, ethambutol; F, fast-multiplying bacteria; H, isoniazid; N, non-multiplying bacteria; R, rifampicin; RSE, relative standard error reported on the approximate
standard deviation scale; S, slow-multiplying bacteria.
aFixed to estimates from application of the MTP model in vitro by Clewe et al.4 2016.
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study). The PD interactions on the death rate of S (INTSRH )
and N (INTNRH ) between rifampicin and isoniazid were
identified and presented in Figure 2 in solid and dashed
red lines, illustrating prediction from the final MTP-GPDI
model with quantified, observed interaction and model-
predicted expected additivity based on the monotherapies.
In R10H25Z150, isoniazid was shown to stimulate the death
rate of N as well, which was not identified in monotherapy.
There are some implications to consider when interpreting
isoniazid effect on the N bacterial state. Due to the different
length of the exposure-response experiments (i.e., 4-week
mono drug treatments vs. 24-week combination treatments),
the composition of the bacterial burden was quite different,
with a much higher number of N bacteria in the 24-week
experiment compared to the 4-week experiment. However,
isoniazid effect on the N bacterial state was not identified in
R10H25 either, but solely in the presence of pyrazinamide in
the triple combination, even though there was no pyrazina-
mide effect identified from monotherapy. Still, because of the
lack of data on isoniazid mono effects at later time points,
we could not clearly distinguish whether pyrazinamide trig-
gered the isoniazid effect on N bacterial state or if this effect
was an effect of isoniazid alone. This aspect of our work
underscores the importance of defining the same setting of
Figure 4 Visual Predictive Check of the final Multistate Tuberculosis Pharmacometric model linked to the General Pharmacodynamic
Interaction model applied to colony forming unit (CFU) data from a tuberculosis-infected experimental mouse model without treatment
(natural growth) and with different drug treatments. Data above the lower limit of quantification (LLOQ) are shown in plots in the first
and third rows, and the horizontal lines represent the LLOQ in plots in the first and third rows. The solid lines are the medians of the
observations and open circles are the observations. Light gray shaded areas represent 95% confidence intervals for the medians. Data
below the LLOQ are shown in plots in the second and fourth rows where the solid lines are the medians of the LLOQ data. Light gray
shaded areas represent 95% confidence intervals for the medians of the LLOQ data. R5, R10, and R20 represent 5, 10, and 20 mg/kg
of rifampicin monotherapy. H12.5, H25, and H50 represent 12.5, 25, and 50 mg/kg of isoniazid monotherapy. R10H25, R10H25Z150, and
R10H25Z150E100 are different combinations using 10 mg/kg of rifampicin, 25 mg/kg of isoniazid, 150 mg/kg of pyrazinamide, and 100
mg/kg of ethambutol.
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experiments for drug efficacy evaluation in monotherapy and
in assessing PD interactions in combinations. In the report
from Grosset et al.,27 the combination of isoniazid and rifam-
pin was bactericidal to a similar magnitude as the combina-
tion of isoniazid, rifampicin, and pyrazinamide, but both of
those two combinations were less effective than the one
combining rifampin and pyrazinamide. They concluded that
there was antagonism between isoniazid and the combina-
tion of rifampicin and pyrazinamide in mice. Later studies
by Almeida et al.28 reported that the antagonism between
isoniazid and the combination of rifampin and pyrazinamide
was dependent on the dose of isoniazid. Increasing the
dose of isoniazid alone resulted in a better antimicrobial
effect. Conversely, increasing the dose of isoniazid in the
combination of rifampicin and pyrazinamide resulted in a
lower antimicrobial effect. Our model-based approach
matches these observations, but surpasses these results
by providing quantitative measures to describe PD interac-
tions (i.e., our model predicted a 0.86 log10 CFU/lungs
higher bacterial load, compared to an expected additivity in
R10H25). An antagonistic interaction (less effect than
expected additivity) between isoniazid and rifampicin was
found in this work (Figure 2a and Figure 3) which is an
agreement with clinical early bacterial activity data from
day 0–14, as reported by Jindani et al.29 A synergistic
interaction on N state bacteria was identified between
rifampicin and ethambutol in this work. This interaction was
only quantifiable by using the GPDI approach, which can
capture interactions between active and inactive drugs, as
interactions are quantified as shift of a PD parameter and
not on the effect level. However, mono effects and interac-
tions arising from ethambutol could not formally be differen-
tiated using the data, because there was no longitudinal
CFU data from mice receiving ethambutol alone, as these
mice became moribund due to a lack of early ethambutol
mono effects. This implies that, in future studies, higher
doses of ethambutol should be studied to establish a com-
plete exposure-response relationship also in monotherapy.
This would allow evaluating longer monotherapy time-
courses to clearly distinguish between mono and combina-
tory effects of ethambutol at later time points of therapy.
Using the MTP model together with the GPDI model, this
study provides estimates of single drug effects together
with a quantitative model-based evaluation framework for
PD interactions among antitubercular drugs in TB drug
development.
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